|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||15.41 - 15.84|
|52 Week Range||12.55 - 21.59|
|Beta (5Y Monthly)||1.21|
|PE Ratio (TTM)||8.39|
|Forward Dividend & Yield||0.78 (5.46%)|
|Ex-Dividend Date||Apr 28, 2019|
|1y Target Est||26.10|
The millions of doses of chloroquine donated to the federal stockpile can now be used to treat COVID-19 patients. At the same time, pharmacists are concerned that prescribing the drug for the novel coronavirus has created shortages of the medication for patients with lupus and rheumatoid arthritis and raises questions about safety.
Novartis and Incyte plan to test their drug Jakavi in patients with coronavirus-caused COVID-19, joining other firms including Roche and Sanofi hoping to repurpose older medicines to help critically ill patients. Jakavi is used in adults with bone marrow cancer, or myelofibrosis, among other conditions. Novartis and Incyte want to see if it helps COVID-19 patients suffering from an immune system overreaction, also called a cytokine storm.
Talks between Bayer AG and plaintiff lawyers to settle claims that the German company's glyphosate-based weedkillers cause cancer have been slowed by the coronavirus pandemic, Bayer's Chief Executive told daily Handelsblatt. Court-appointed mediator Ken Feinberg told Reuters last month that the talks were slowed by the pandemic. In the Handelsblatt interview, CEO Baumann reiterated remarks he made at the end of February that he was under no time pressure to strike a settlement deal and that he would not submit to a schedule or deadline.
The global coronavirus case count surpassed 735,000 Monday, with more than 35,000 deaths reported, according to Johns Hopkins.
The Food and Drug Administration approved the anecdotally promising malaria drug for emergency use to treat hospitalized patients for Covid-19.
Merck & Co Inc said on Saturday that vericiguat, an investigational drug for patients with worsening chronic heart failure, met the primary efficacy endpoint in the VICTORIA trial. The VICTORIA trial is a Phase 3 study evaluating the efficacy and safety of the drug vericiguat, which is being jointly developed with Bayer AG, the company said. Compared with a placebo, the drug reduced the risk of heart failure hospitalization or cardiovascular death in heart failure patients with reduced ejection fraction (HFrEF) when given in combination with available therapies, Merck said.
WINNIPEG, Manitoba/CHICAGO, March 26 (Reuters) - North America's biggest farm suppliers are accelerating shipments of fertilizer, seeds and agricultural chemicals to crop-growing regions in an unprecedented race against the coronavirus that threatens to disrupt planting season. The timing could not be worse for farmers preparing to plant crops. Disruptions in deliveries of fertilizer, seeds or chemicals could reduce harvests and incomes for U.S. farmers who were hoping this year to sell more crops to China under the terms of a trade agreement signed in January.
India has axed the royalties that local seed companies pay to German drugmaker Bayer AG for Monsanto's genetically modified (GM) cotton, a government order said, after cutting them back since 2016. More than 45 local cotton seed companies pay royalties to Monsanto, acquired by Bayer in 2018, for GM cotton using a gene that produces its own pesticide.
President Donald Trump and the Food and Drug Administration commissioner appeared to exchange conflicting statements about how a decades-old antimalaria drug is being used to treat COVID-19.
The U.S. is wrapping up the first full business week feeling the brunt of the COVID-19 pandemic, with restaurants, bars, parks, retailers and workplaces shut down in many cities across the nation and three states in lockdown.
President Trump touts chloroquine, which has been controversial. Other drugs may find some success in the weeks or months ahead.
Throw away the old playbook, says Bernstein strategist Inigo Fraser Jenkins. Government policy, not the usual factors such as valuation, will drive the stock market for a while
This has been another tough pill to swallow: France’s health ministry has suggested that certain painkillers could aggravate the effects of the coronavirus. Olivier Veran tweeted last week that some nonsteroidal anti-inflammatories (aka NSAIDs) worsen the effects of COVID-19, the disease caused by the novel coronavirus. If you have a fever, take paracetamol [aka acetaminophen].
Shares of Teva Pharmaceutical Industries Ltd. gained 13% in premarket trading on Friday following a Thursday night announcement that the drugmaker will donate more than 6 million doses of hydroxychloroquine sulfate tablets in the U.S. this month. Chloroquine, a longtime malaria drug that is sometimes used as a treatment for rheumatoid arthritis, is being floated as a potential treatment for people sickened by the novel coronavirus by the Trump administration. Teva said in a news release that the drug, which has not received Food and Drug Administration approval as a treatment for COVID-19, has been requested by government officials in efforts to treat the disease. Bayer AG and Mylan have also said they will produce chloroquine therapies as a result of the COVID-19 pandemic. Teva's stock is down 29.9% year-to-date, while the S&P 500 has dropped 25.4%.
U.S. listed shares of Bayer AG rose 3% in trading on Thursday afternoon after it said it had donated three million tablets of Resochin, a chloroquine product, to the U.S. The German drugmaker said that it is seeking an emergency use authorization for the drug in the U.S., where it is not approved. Health care providers in countries like China and France have been using chloroquine-based therapies to treat COVID-19 patients as there are no proven treatments for the disease. At a news conference on Thursday, President Donald Trump talked up use of the antimalaria drug to treat patients who have the novel coronavirus, and FDA commissioner Stephen Hahn said that while chloroquine has been approved for other indications, it would still need to go through clinical trials. Bayer's stock is down 34% year-to-date, while the S&P 500 has dropped 25%.
An old malaria treatment that has been tried with some success against the new coronavirus and was touted by U.S. President Donald Trump at a news briefing earlier on Thursday is in short supply as demand surges amid the fast-spreading outbreak. The American Society of Health-System Pharmacists (ASHP), which maintains a list of drugs in shortage independent of the U.S. Food and Drug Administration's list, added the generic malaria drug hydroxychloroquine to its list on Thursday. The new coronavirus, which causes the highly contagious COVID-19 respiratory illness, emerged in December in Wuhan, China and has spread throughout the world.
Bayer AG said on Thursday it has donated 3 million tablets of the malaria drug Resochin to the U.S. government for potential use to treat COVID-19. Resochin, made of chloroquine phosphate and an approved treatment for malaria, is being evaluated in China for its potential use against COVID-19, the disease caused by the fast-spreading coronavirus. Bayer said the drug is currently not approved for use in the United States and the company is working with appropriate agencies on an emergency use authorization for its use in the United States.
Shares of the German drugs and pesticides company have come under immense pressure since it lost the first U.S. lawsuit claiming that glyphosate-based Roundup, acquired via its takeover of Monsanto in 2018, causes cancer. Bayer had also said that based on average analyst predictions of a settlement worth about $10 billion, the company would not have to write down the value of the $63 billion Monsanto acquisition. The settlement still appears poised to end up around $10 billion, the WSJ report https://www.wsj.com/articles/bayer-advances-toward-resolving-roundup-litigation-11584124255?mod=searchresults&page=1&pos=3 said, citing a person familiar with the matter.